Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $39.29 -1.55%
EPS Growth %: -213.5%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -213.5%
Financial Fact:
Total non-operating expense: -10.18M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.24), $0.08 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $16.31 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parabolic reports preliminary Q3 2026 revenue of $4.7 million
- Pfizer to cut 330 jobs at Sicily plant, unions say
- SpaceX (SPCX) call put ratio 1.3 calls to 1 put as share price down 1.9%
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
